Bayer offers $2.4bn for Xofigo partner Algeta
This article was originally published in Scrip
Executive Summary
Bayer has made a $2.4bn offer for Algeta, its Norwegian partner for the prostate cancer drug Xofigo (radium-223 dichloride). The preliminary offer represents a 27% premium to Algeta's closing share price on the Oslo stock exchange on 25 November before the bid was made public.